Neurological updates: neurological complications of CAR-T therapy

Tallantyre, Emma, Evans, Nia, Parry-Jones, Jack, Morgan, Matt, Jones, Ceri and Ingram, Wendy 2020. Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology 10.1007/s00415-020-10237-3 Item availability restricted.

PDF - Accepted Post-Print Version Restricted to Repository staff only until 2 November 2021 due to copyright restrictions. Download (572kB)

Abstract

Chimeric antigen receptor (CAR) expressing T-cells now offer an effective treatment option for people with previously refractory B-cell malignancies and are under development for a wide range of other tumours. However, neurological toxicity is a common complication of CAR T-cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term immune effector cell-associated neurotoxicity syndrome (ICANS) has been used to describe and grade neurotoxicity seen after CAR T-cells and other similar therapies. ICANS following CAR-T therapy is usually self-limiting but can necessitate admission to the intensive care unit and is rarely fatal. As CAR-T therapies enter routine clinical practice, it is important for neurologists to be aware of the nature of neurological complications. Here we summarise the clinical manifestations, mechanisms, investigations and recommended treatment of CAR-T related neurotoxicity, focusing on the licensed CD19 products.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Medicine Neuroscience and Mental Health Research Institute (NMHRI)
Publisher:	Springer
ISSN:	0340-5354
Date of First Compliant Deposit:	6 October 2020
Date of Acceptance:	18 September 2020
Last Modified:	20 Jan 2021 11:21
URI:	http://orca.cf.ac.uk/id/eprint/135340

Actions (repository staff only)

Edit Item